Amgen earnings beat expectations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
AppFolio earnings beat analyst expectations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
American Riviera Bank reports strong growth
Santa Barbara-based American Riviera Bank reported net income of $4.82 million for the nine months ended Sept. 30, a 10 percent increase in net income from the $4.4 million for the same reporting period in the prior year. The bank continues to experience significant growth, reporting $697 million in total assets as of Sept. 30, Read More →
Our view: How Cal Poly SLO can achieve diversity
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Two Central Coast technology companies raise $150 million
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Deckers earnings beat analyst expectations
Goleta-based footwear and apparel company Deckers Brands reported an 8 percent increase in its second quarter revenue Oct. 24, beating analyst expectations with $2.71 in earnings per share. The company also announced the appointment of a new chairman to its board of directors, board member and former CFO of Coach Inc., Mike Devine. Former chairman Read More →
Amgen cuts list price of Repatha by 60 percent
Amgen doubled down on its decision to slash the list price of one of its newest drugs, Repatha, listing it for all patients at $5,840 per year. The Thousand Oaks-based biotech giant reduced the list price by 60 percent for some patients for the cholesterol medication a year before, and the announcement Oct. 24 discontinues Read More →
